Connect
← Return to Good news, Bensocatib Trials Continue for Bronchieactasis
Discussion
Good news, Bensocatib Trials Continue for Bronchieactasis
MAC & Bronchiectasis | Last Active: Aug 20 1:10pm | Replies (24)Comment receiving replies
Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/ so all of the members talking about this study could be in one place.
Like @sueinmn mentioned, the article linked in this discussion is a stock report. Have you been able to track down the study data link that you are referring to? I found one article, but it is from 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2021713.
Replies to "Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/..."
Connect
The news just came out yesterday, so there aren’t medical journal articles on this top line data at this point in time.
I created this general discussion of ongoing active clinical trials at Colleen Young’s suggestion. But if you wish to move this to a previous discussion on brensocatib that makes sense as well.
You can read about the clinical trial by clicking on the link below. Also, if you Google “Aspen” and “brensocatib” you will find earlier articles from clinical and scientific journals.
https://classic.clinicaltrials.gov/ct2/show/NCT04594369
Many of us have been waiting for this information ever since the trial completed its in enrollment in March 2023 of 1700 participants. Yesterday‘s news was tremendously significant for those of us with bronchiectasis who have frequent exacerbations. Even at the lower dose, there was approximately a 20% reduction in exacerbations. If approved by the FDA, this will be the first drug approved specifically for BE.